Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

被引:5
|
作者
Flury, Philipp [1 ,2 ]
Breidenbach, Julian [3 ]
Krueger, Nadine [4 ]
Voget, Rabea [3 ]
Schaekel, Laura [3 ]
Si, Yaoyao [3 ]
Krasniqi, Vesa [3 ]
Calistri, Sara [1 ,2 ]
Olfert, Matthias [5 ]
Sylvester, Katharina [3 ]
Rocha, Cheila [4 ]
Ditzinger, Raphael [1 ,2 ]
Rasch, Alexander [1 ,2 ]
Poehlmann, Stefan [4 ,5 ]
Kronenberger, Thales [1 ,2 ,6 ,7 ]
Poso, Antti [1 ,2 ,6 ]
Rox, Katharina [8 ,9 ]
Laufer, Stefan A. [1 ,2 ]
Mueller, Christa E. [2 ,3 ]
Guetschow, Michael [3 ]
Pillaiyar, Thanigaimalai [1 ,2 ]
机构
[1] Eberhard Karls Univ Tubingen, Inst Pharm Pharmaceut Med Chem, D-72076 Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen Ctr Acad Drug Discovery, D-72076 Tubingen, Germany
[3] Univ Bonn, Pharmaceut Inst, PharmaCtr Bonn, Pharmaceut & Med Chem, D-53121 Bonn, Germany
[4] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, D-37077 Gottingen, Germany
[5] Univ Goettingen, Fac Biol & Psychol, D-37073 Gottingen, Germany
[6] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland
[7] Excellence Cluster Controlling Microbes Fight Inf, D-72076 Tubingen, Germany
[8] Helmholtz Ctr Infect Res HZI, Dept Chem Biol, D-38124 Braunschweig, Germany
[9] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, D-38124 Braunschweig, Germany
关键词
COVID-19; cathepsininhibitors; main protease; peptidomimetics; SARS-CoV-2; viral entry; MAIN PROTEASE; CYSTEINE; ENTRY; REACTIVITY; DISCOVERY;
D O I
10.1021/acsptsci.3c00313
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural diversity was realized by combinations of different C-terminal warhead functions and N-terminal capping groups, while a central Leu-Phe fragment was maintained. Several compounds were identified as promising cathepsin L and S inhibitors with K-i values in the low nanomolar to subnanomolar range, for example, the peptide aldehydes 9a and 9b (9a, 2.67 nM, CatL; 0.455 nM, CatS; 9b, 1.76 nM, CatL; 0.512 nM, CatS). The compounds' inhibitory activity against the main protease of SARS-CoV-2 (M-pro) was additionally investigated. Based on the results at CatL, CatS, and M-pro, selected inhibitors were subjected to investigations of their antiviral activity in cell-based assays. In particular, the peptide nitrile 11e exhibited promising antiviral activity with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity. High metabolic stability and favorable pharmacokinetic properties make 11e suitable for further preclinical development.
引用
收藏
页码:493 / 514
页数:22
相关论文
共 50 条
  • [1] Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors
    Park, Seung Bum
    Irvin, Parker
    Hu, Zongyi
    Khan, Mohsin
    Hu, Xin
    Zeng, Qiru
    Chen, Catherine
    Xu, Miao
    Leek, Madeleine
    Zang, Ruochen
    Case, James Brett
    Zheng, Wei
    Ding, Siyuan
    Liang, T. Jake
    MBIO, 2022, 13 (01):
  • [2] Design, synthesis, and biological evaluation of dithiocarbamate derivatives as SARS-CoV-2 M pro inhibitors
    Peng, Jin-Qi
    Xiao, Ya-Qi
    Long, Jiao
    Zhang, Shuang-Shuang
    Zhu, Yuan-Yuan
    Gu, Shuang-Xi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 114
  • [3] Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
    Xiao, Ya-Qi
    Long, Jiao
    Zhang, Shuang-Shuang
    Zhu, Yuan -Yuan
    Gu, Shuang-Xi
    BIOORGANIC CHEMISTRY, 2024, 147
  • [4] Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: Design, synthesis, biological evaluation, and structure-activity relationships exploration
    Zhang, Heng
    Li, Jing
    Toth, Karoly
    Tollefson, Ann E.
    Jing, Lanlan
    Gao, Shenghua
    Liu, Xinyong
    Zhan, Peng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 96
  • [5] Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
    Mengist, Hylemariam Mihiretie
    Dilnessa, Tebelay
    Jin, Tengchuan
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [6] Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
    Tan, Bin
    Sacco, Michael
    Tan, Haozhou
    Li, Kan
    Joyce, Ryan
    Zhang, Xiujun
    Chen, Yu
    Wang, Jun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 259
  • [7] Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2
    Yan, Yong
    Liu, Hanwen
    Wu, Di
    Gu, Zhihao
    Guo, Wenhao
    Yao, Hequan
    Lin, Kejiang
    Li, Xuanyi
    FUTURE MEDICINAL CHEMISTRY, 2024, 16 (09) : 887 - 903
  • [8] Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L
    Meewan, Ittipat
    Kattoula, Jacob
    Kattoula, Julius Y.
    Skinner, Danielle
    Fajtova, Pavla
    Giardini, Miriam A.
    Woodworth, Brendon
    McKerrow, James H.
    Lage de Siqueira-Neto, Jair
    O'Donoghue, Anthony J.
    Abagyan, Ruben
    PHARMACEUTICALS, 2022, 15 (06)
  • [9] Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2
    Yang, Hanxi
    You, Mengyuan
    Shu, Xiaoyang
    Zhen, Jingyao
    Zhu, Mengwei
    Fu, Tiantian
    Zhang, Yan
    Jiang, Xiangrui
    Zhang, Leike
    Xu, Yechun
    Zhang, Yumin
    Su, Haixia
    Zhang, Qiumeng
    Shen, Jingshan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 257
  • [10] Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
    Ashraf-Uz-Zaman, Md
    Chua, Teck Khiang
    Li, Xin
    Yao, Yuan
    Moku, Bala Krishna
    Mishra, Chandra Bhushan
    Avadhanula, Vasanthi
    Piedra, Pedro A.
    Song, Yongcheng
    ACS INFECTIOUS DISEASES, 2024, 10 (02): : 715 - 731